Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition

BACKGROUND: In ALK-positive advanced NSCLC, crizotinib has a high response rate and effectively increases quality of life and survival. CT measurement of the tumor may insufficiently reflect the actual tumor load changes during targeted therapy with crizotinib. We explored whether (18)F-FDG PET meas...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerner, Gerald S. M. A., Koole, Michel J. B., Bongaerts, Alphons H. H., Pruim, Jan, Groen, Harry J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854442/
https://www.ncbi.nlm.nih.gov/pubmed/27137772
http://dx.doi.org/10.1371/journal.pone.0149955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854442/
https://www.ncbi.nlm.nih.gov/pubmed/27137772
http://dx.doi.org/10.1371/journal.pone.0149955

Ejemplares similares